-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Keyuan Pharmaceutical makes a strong comeback at CPHI China 2025, joining hands with global partners to discuss new opportunities for growth!
Publish Time:
2025-06-24
On the eve of the exhibition opening, Gao Chunpo, Chairman and President of Keyuan Pharmaceutical, personally led the international marketing team to host an international VIP client symposium, fostering in-depth communication and exchanges with partners from around the globe.
From June 24 to 26, the 23rd China Pharmaceutical Ingredients Exhibition (CPHI China 2025) was grandly held at the Shanghai New International Expo Center. As a leading enterprise in the niche segment of chemical API products, Keyuan Pharmaceutical (stock code: 301281.SZ) was once again invited to showcase its outstanding product portfolio and internationalization strategy, demonstrating its commitment to sharing new opportunities and fostering collaborative growth with industry peers worldwide.
On the eve of the exhibition opening, Gao Chunpo, Chairman and President of Keyuan Pharmaceutical, personally led the international marketing team to host an international VIP client symposium, fostering in-depth communication and exchange with partners from around the globe.
Chairman Gao Chunpo stated at the meeting: "Industrial globalization is our unwavering and vital strategy. Through this dialogue session, we aim to further strengthen our ties with partners, gain a deeper understanding of each other's needs, jointly explore new trends in industry development, and work together to unlock even more opportunities for collaboration."
At the E2A10 booth, the harmonious blend of tech blue and medical white created a clean, bright, and inviting atmosphere. A lineup of core products—each proudly certified by prestigious international authorities such as the U.S. FDA, the EU CEP, and South Korea’s MFDS—was neatly displayed, drawing in numerous existing and prospective customers who stopped by to observe and inquire. Chairman Gao Chunpo, accompanied by the marketing team, engaged in insightful discussions with clients from around the globe. The venue buzzed with activity, as crowds gathered and the energy remained vibrant throughout.
As a company that has been deeply rooted in the chemical API industry for over 20 years, Keyuan Pharmaceutical fully understands that innovation is the key to sustaining the company's vitality. Currently, Keyuan Pharmaceutical is driving growth through the innovative integration of chemical and biosynthetic technologies, continuously strengthening its core strengths in chronic disease areas such as diabetes, cardiovascular health, and central nervous system disorders. At the same time, the company is actively expanding into emerging business segments like cosmetic ingredients, high-end pharmaceutical excipients, and functional food additives, thereby building an industry ecosystem centered around "APIs combined with multi-sector collaboration" and comprehensively shaping new competitive advantages for the company's future development.
Currently, the global pharmaceutical industry is undergoing profound transformations and facing significant challenges. Policy adjustments, intensifying market competition, and evolving global supply chains have introduced considerable uncertainty into the industry's development. In response to these uncertainties, Keyuan Pharmaceutical has consistently upheld its core values of "long-termism, product-centricity, and altruism," remaining committed to a long-term perspective, staying firmly product-driven, and prioritizing actions that benefit both our partners and the broader industry.
This participation in CPHI China 2025 is not only an important platform for Keyuan Pharmaceutical to showcase its strength, but also a crucial opportunity for the company to further expand into international markets. Moving forward, Keyuan Pharmaceutical will steadily advance its globalization strategy with an even more determined pace and an increasingly open mindset, continuously enhancing both product quality and service standards, and contributing greater, more impactful efforts to the global pharmaceutical and healthcare industry!
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline